A total of 12 of these 14 patients (2 of whom had ductal carcinoma in situ; 9 luminal, 3 luminal/HER‐2) received postoperative adjuvant chemotherapy. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.